Copyright
©The Author(s) 2021.
World J Gastroenterol. Mar 21, 2021; 27(11): 1090-1100
Published online Mar 21, 2021. doi: 10.3748/wjg.v27.i11.1090
Published online Mar 21, 2021. doi: 10.3748/wjg.v27.i11.1090
Table 2 Tolerability Scores in the inflammatory bowel disease and non-inflammatory bowel disease cohorts
| Prep Kit-C (n = 145) | Moviprep (n = 143) | P value | |
| IBD, n = 95 | 9.67 ± 4.87; n = 47 | 10.89 ± 5.21; n = 48 | 0.25 |
| Non-IBD, n = 193 | 11.61 ± 5.32; n = 98 | 12.32 ± 5.35; n = 95 | 0.36 |
- Citation: Mohsen W, Williams AJ, Wark G, Sechi A, Koo JH, Xuan W, Bassan M, Ng W, Connor S. Prospective single-blinded single-center randomized controlled trial of Prep Kit-C and Moviprep: Does underlying inflammatory bowel disease impact tolerability and efficacy? World J Gastroenterol 2021; 27(11): 1090-1100
- URL: https://www.wjgnet.com/1007-9327/full/v27/i11/1090.htm
- DOI: https://dx.doi.org/10.3748/wjg.v27.i11.1090